Multiple Myeloma Clinical Trials

A listing of Multiple Myeloma medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 78 clinical trials
Isatuximab in Combination With Novel Agents in RRMM - Master Protocol

Primary Objectives: Part 1 (dose finding, experimental substudies): To determine or confirm the recommended dose of novel agents when combined with isatuximab with or without dexamethasone in participants with RRMM. Part 2 (expansion, experimental substudies): To demonstrate the clinical benefit of novel agents combined with isatuximab with or without dexamethasone …

  • 0 views
  • 14 Jun, 2021
  • 9 locations
Treatment With Lenalidomide Bendamustine and Prednisone (RBP) in Patients With Relapsed or Refractory Multiple Myeloma

Define maximum tolerable dose of the combination lenalidomide, bendamustine, prednisone.

cancer
prednisone
lenalidomide
refractory multiple myeloma
  • 64 views
  • 08 Nov, 2020
Third-line Therapy of Multiple Myeloma a Prospective Phase I /II Trial

on the response rate in patients with relapsed or refractory or progressive multiple myeloma(MM). Phase I: to determine the lenalidomide dse for the phase II part (5 mg or 10 mg or 15 mg

vasectomy
aspirin
progressive disease
heparin
cancer
  • 14 views
  • 08 Nov, 2020
  • 1 location
Study of Ipilimumab After Stem Cell Transplantation in People With Relapsed/Refractory Multiple Myeloma

This study will test the safety of ipilimumab to see what effects, if any, the drug has when used as maintenance therapy for people with relapsed/refractory multiple myeloma who have received

  • 0 views
  • 04 Feb, 2021
  • 7 locations
Antigen-specific T Cell Therapy for Patients With Relapsed Refractory Multiple Myeloma

populations of CD8+ T cells targeting multiple Myeloma associated antigen peptides in patients with relapsed refractory multiple myeloma (MM). The study will enroll patients with MM who have relapsed

  • 0 views
  • 27 Jan, 2021
  • 4 locations
  • 20 views
  • 03 Feb, 2021
  • 45 locations
Myeloma-Developing Regimens Using Genomics (MyDRUG)

. The genetic sequencing of the patient's tumor is required via enrollment to the MMRF002 study: Clinical-grade Molecular Profiling of Patients with Multiple Myeloma and Related Plasma Cell

  • 18 views
  • 13 Mar, 2021
  • 14 locations
A Phase I/II Trial of Romidepsin (Depsipeptide) and Bortezomib in Patients With Relapsed Myeloma

Myeloma. The second phase of the study will establish whether depsipeptide, bortezomib and dexamethasone is effective in the treatment of patients with multiple myeloma. The study will also

measurable disease
maintenance therapy
platelet count
dexamethasone
plasmacytoma
  • 31 views
  • 07 Nov, 2020
  • 1 location
Study of T Cells Targeting CD19/BCMA (CART-19/BCMA) for High Risk Multiple Myeloma Followed With Auto-HSCT

CART therapy has showed good safety and efficacy in treatment of lymphoma and acute lymphoblastic leukemia. Researchers want to see if this helps people with high risk multiple myeloma after

  • 37 views
  • 29 May, 2021
  • 1 location
Clinical Trial Using Humanized CART Directed Against BCMA (ARI0002h) in Patients With Relapsed/Refractory Multiple Myeloma to Proteasome Inhibitors Immunomodulators and Anti-CD38 Antibody.

To assess the safety and efficacy of CARTBCMA ARI0002h in patients with relapsed/refractory multiple myeloma who have received treatment with proteasome inhibitor, immunomodulatory drug and anti

  • 0 views
  • 26 Jan, 2021
  • 5 locations